

Summary of risk management plan for Zomylac

This is a summary of the risk management plan (RMP) for Zomylac. The RMP details important risks of Zomylac, how these risks can be minimised and how more information will be obtained about Zomylac risks and uncertainties (missing information).

Zomylac summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Zomylac should be used.

I. The medicine and what it is used for

Zomylac is authorised for treatment of the following infections in children from 6 weeks of age and adults, when caused by susceptible organisms.

- Upper urinary tract infections.
- Lower complicated urinary tract infections.
- Acute exacerbation of chronic bronchitis. - Shigellosis.
- Nocardiosi
- Prophylaxis and treatment of infections caused by *Pneumocystis jirovecii* and *toxoplasma gondii*.

It contains 16 mg/ml trimethoprim and 80 mg/ml sulfametoxazole as the active substances and is given intravenously.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Zomylac, together with measures to minimise such risks and the proposed studies for learning more about Zomylac's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals

Important advice on the medicine's packaging

The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly

The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Zomylac are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered or taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Zomylac. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Summary of safety concerns	
Important identified risk	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Zomylac.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Zomylac.